Welcome to our dedicated page for ProKidney SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.
PROKIDNEY CORP. director Alan Lotvin received a grant of stock options as part of non-employee director compensation. The award covers 135,000 options to buy Class A Common Stock at an exercise price of $1.81 per share, all held directly.
The options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. Following this grant, Lotvin holds 135,000 director stock options linked to the company’s Class A Common Stock.
PROKIDNEY CORP. director Jose Ignacio Jimenez Santos received a grant of 135,000 stock options under the company’s non-employee director compensation policy. The options allow him to buy Class A Common Stock at an exercise price of $1.81 per share and expire on May 28, 2036.
The options will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual general shareholder meeting. After this award, he holds 135,000 derivative securities related to Class A Common Stock directly.
PROKIDNEY CORP. director Jennifer A. Fox received a grant of stock options as part of non-employee director compensation. She was awarded 135,000 director stock options, each allowing her to buy one share of Class A Common Stock at an exercise price of $1.81.
The options vest in full on the earlier of one year from the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. After this grant, she holds 135,000 options directly, and this is a compensation award rather than an open-market share purchase.
PROKIDNEY CORP. director William F. Doyle reported receiving a grant of stock options as part of non-employee director compensation. He was awarded 135,000 director stock options, each allowing him to buy one share of Class A Common Stock at an exercise price of $1.81 per share.
The options were granted at no upfront cost and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting. After this grant, Doyle holds 135,000 options directly, with an expiration date in 2036.
PROKIDNEY CORP. director Uma Sinha received a grant of options to buy 135,000 shares of Class A Common Stock at an exercise price of $1.81 per share. These director options were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of one year from grant or the next annual general shareholder meeting.
PROKIDNEY CORP. director and 10% owner Pablo G. Legorreta received a grant of director stock options covering 135,000 shares of Class A Common Stock. The options have an exercise price of $1.81 per share and expire on May 28, 2036. They were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting.
PROKIDNEY CORP. director Brian JG Pereira received a grant of 135,000 director stock options as part of the company’s non-employee director compensation policy. The options have an exercise price of $1.81 per share, expire on May 28, 2036, and cover 135,000 shares of Class A common stock. According to the terms, the options will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting, and this grant brings his reported option holdings in this award to 135,000 options.
ProKidney Corp. reported the results of its 2026 Annual Meeting of Stockholders. Shareholders elected William F. Doyle, Alan M. Lotvin, M.D., and Brian J.G. Pereira to the Board of Directors, each for a three-year term ending at the 2029 annual meeting. Doyle received 196,164,585 votes for and 1,459,235 withheld; Lotvin received 193,179,768 for and 4,444,052 withheld; Pereira received 197,002,580 for and 621,240 withheld. Shareholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 239,091,167 votes for, 729,165 against, and 382,882 abstentions.
ProKidney Corp. reported a first-quarter 2026 net loss before noncontrolling interest of $42.6 million, compared with $38.0 million a year earlier, as it increased investment in its lead cell therapy, rilparencel. Revenue was minimal at $226 thousand.
Cash, cash equivalents and marketable securities totaled $224.9 million as of March 31, 2026, down from $270.0 million at year-end 2025, and are expected to fund operations into mid‑2027. Research and development expenses rose to $33.8 million, while general and administrative expenses declined to $11.3 million.
Clinically, the Phase 3 REGEN‑006 (PROACT 1) trial in advanced chronic kidney disease remains on track to complete enrollment for the accelerated-approval eGFR slope analysis in mid‑2026, with pivotal topline results anticipated in Q2 2027. Prior Phase 2 REGEN‑007 data showed a 4.6 mL/min/1.73m² improvement in annual eGFR slope in Group 1 after bilateral rilparencel injections.
ProKidney Corp. reported a larger net loss as it advances its lead kidney therapy. For the three months ended March 31, 2026, net loss available to Class A stockholders was $20.0 million, or $0.14 per share, versus $16.7 million or $0.13 a year earlier.
Research and development spending rose to $33.8 million, mainly from higher Phase 3 PROACT 1 trial and manufacturing costs, while general and administrative expenses fell to $11.3 million on lower equity-based compensation and professional fees. Cash used in operating activities was $41.7 million.
As of March 31, 2026, ProKidney held $101.9 million in cash and cash equivalents and $123.0 million in marketable securities, for total assets of $292.8 million. The company expects this liquidity to fund operations into mid-2027 while it runs its Phase 3 study of rilparencel, with key efficacy readouts anticipated in 2027 and 2029.